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BACKGROUND: A recent summary-level meta-analysis comprising randomized, 
controlled trials (RCTs) of femoropopliteal paclitaxel-coated balloon and stent 
intervention identified excess late mortality in the paclitaxel-treated patients.
METHODS: We evaluated the safety of the Stellarex drug-coated balloon (DCB) for 
femoropopliteal artery disease with an independently performed meta-analysis of 
patient-level data from all patients in the Stellarex femoropopliteal clinical program. 
To compare mortality after DCB or uncoated percutaneous transluminal angioplasty 
(PTA), we aggregated data from 2 RCTs comprising 419 patients treated with DCB 
and 170 patients treated with PTA. In an additional analysis, data were aggregated 
from 6 poolable Stellarex DCB studies (2 RCTs, 3 single-arm studies, and 1 registry). 
All serious adverse events including deaths were adjudicated by a blinded, third-
party, independent Clinical Events Committee. Kaplan–Meier estimates in the 
RCTs were compared with restricted mean survival time. Predictors of death were 
assessed with hazard ratios (HRs) and Cox proportional hazards modeling.
RESULTS: Baseline characteristics were similar in the patients treated with DCB 
and PTA in the pooled RCT analysis, with the exception that the DCB cohort was 
younger (67.4±9.7 versus 69.4±9.4 years, P=0.02), smoked more frequently 
(86.6% versus 78.8%, P=0.02), and were less often treated for recurrent lesions 
(8.8% versus 14.7%, P=0.04). In the RCTs, patients treated with DCB had all-
cause mortality rates that were not different from those of patients treated with 
PTA (Kaplan–Meier estimates 1.8±0.7% versus 1.3±0.9%, 6.5±1.2% versus 
5.9±1.9%, and 9.3±1.5% versus 9.9±2.4% at 1, 2, and 3 years, respectively, 
P=0.86). All-cause mortality rates were similar in a 1906-patient pooled 
nonrandomized DCB data set (Kaplan–Meier estimates of 2.1%, 4.9%, and 
7.0% at 1, 2, and 3 years, respectively). Clinical Events Committee–adjudicated 
causes of death were balanced between the DCB and PTA cohorts. Multivariable 
Cox modeling identified age (HR, 1.06; 95% CI, 1.04–1.08; P<0.001), diabetes 
mellitus (HR, 1.42; 95% CI, 1.01–2.00; P=0.04), congestive heart failure (HR, 
1.88; 95% CI, 1.12–3.16; P=0.02), and renal insufficiency (HR, 2.00; 95% CI, 
1.33–3.01; P<0.001) as predictors of mortality. Paclitaxel exposure was unrelated 
to mortality (HR, 1.04; 95% CI, 0.98–1.10; P=0.23).
CONCLUSIONS: The mortality rates for patients treated with the DCB and 
uncoated PTA were indistinguishable over 3-year follow-up. Additional patient-
level, adequately powered meta-analyses with larger RCT data sets will be 
needed to confirm the generalizability of these findings.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique 
identifiers: NCT02110524, NCT01858363, NCT01858428, NCT03421561, 
NCT01912937, NCT01927068, and NCT02769273.
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Percutaneous transluminal angioplasty (PTA) has long been a mainstay of femoropopliteal peripheral arterial disease (PAD) treatment.1 As a minimally in-
vasive modality, PTA has advantages over open surgical 
revascularization and avoids the obligatory, systematic 
need for implantation of a permanent metallic arterial 
stent.2 The durability of femoropopliteal PTA, however, 
is not ideal. When patients with femoropopliteal disease 
are treated with uncoated balloons, up to 47.4% expe-
rience restenosis in the first year after treatment.3
Drug-coated balloons (DCBs) are effective in treat-
ing de novo or restenotic lesions of the femoropopliteal 
arteries.4 Paclitaxel is a cytostatic and cytotoxic agent 
widely used to treat various malignancies, and its thera-
peutic window and pharmacokinetic behavior is well-
described.5 Paclitaxel has significantly decreased the 
risk of restenosis when delivered to the vessel wall with 
DCBs and drug-eluting stents in patients with femoro-
popliteal disease. In previous studies, patients who were 
treated with DCBs had improved target vessel patency 
and significant reductions in late lumen loss and tar-
get vessel revascularization in comparison with patients 
treated with PTA.6–10 Current Society for Cardiovascular 
Angiography and Interventions guidelines recommend 
DCB as a standard treatment option for femoropopli-
teal artery disease.11
A recent systematic review and meta-analysis of 
summary-level data from 28 randomized, controlled 
trials (RCTs) suggested an increased risk of death after 
femoropopliteal artery DCB beginning 2 years after the 
DCB procedure.12 Furthermore, the risk of death was 
incrementally associated with exposure to paclitaxel, 
leading the authors to speculate that late paclitaxel 
toxicity may be contributing to the observed higher 
mortality. This analysis has been criticized for its lack of 
long-term, homogeneous, patient-level data that might 
have identified confounding factors to better explain 
the observations.12
The present study examines the safety profile of the 
Stellarex DCB in comparison with uncoated PTA, ana-
lyzing patient-level data from the worldwide Stellarex 
femoropopliteal clinical trials. The study was designed to 
avoid many of the limitations of the recently published, 
summary-level meta-analysis. An independent third par-
ty, Syntactx, performed the analysis using patient-level 
data and cause-specific adjudicated deaths, homoge-
neous populations treated with the same paclitaxel-
coated device, and 3-year follow-up after treatment.
METHODS
Data Sources
Because of the sensitive nature of the data collected for 
this study, requests to access the data set from qualified 
researchers trained in human subject confidentiality protocols 
may be sent to Philips, IGT-D Medical Information Services 
Department at 1-877-878-0012 or medicalinformation.ser-
vices@philips.com.
The study population comprised 2523 patients: 2353 
treated with the DCB and 170 treated with uncoated PTA. The 
data set included the 7 studies that comprised the Stellarex 
femoropopliteal clinical program (Table 1). The ILLUMENATE 
EU RCT trial (CVI Drug-coated Balloon European Randomized 
Clinical Trial) and the ILLUMENATE Pivotal trial (Pivotal Trial of 
Clinical Perspective
What Is New?
• A patient-level meta-analysis of 2 randomized, 
controlled trials has been conducted from the ILLU-
MENATE clinical program that demonstrated no 
difference in mortality when the Stellarex paclitaxel-
coated balloon was compared with uncoated percu-
taneous transluminal angioplasty through 3 years.
• A paclitaxel dose–dependent effect was also not 
evident.
• The use of Stellarex paclitaxel-coated balloon has 
not correlated to late all-cause mortality.
What Are the Clinical Implications?
• Paclitaxel-coated balloons have been suggested to 
be a factor in late all-cause mortality at 2 and 5 
years posttreatment.
• The implication derives from a meta-analysis pub-
lished by Katsanos et al in 2018.
• Although the relationship of paclitaxel use and 
mortality was found to be statistically significant in 
that meta-analysis, the causal relationship has not 
been established.
• Although freedom from target lesion revasculariza-
tion is improved with the use of a paclitaxel-coated 
balloon, the relationship to late all-cause mortality 
must be determined.
Table 1. Patient Cohorts From the Stellarex Femoropopliteal Clinical 
Program
Study
Study 
Design
Patients 
Included Geography
Follow-
Up, mo
ILLUMENATE EU 
RCT
RCT 289 Europe 60 
ILLUMENATE 
Pivotal9
RCT 300 United States, 
Europe
60 
ILLUMENATE 
Global13
Single-arm 372 Europe, New 
Zealand, Australia
60 
ILLUMENATE 
Global ISR
Single-arm 112 Europe, New 
Zealand, Australia
60 
ILLUMENATE PK9 Single-arm 25 New Zealand 24 
ILLUMENATE FIH14 Single-arm 79 Europe 24 
SAVER Registry Single-arm 1346 Unspecified 36 
FIH indicates first in human; ISR, in-stent restenosis; PK, pharmacokinetic; 
and RCT, randomized, controlled trial.
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a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon)9 
are prospective, multicenter, randomized, single-blinded 
clinical trials that included control arms of patients treated 
with uncoated PTA. ILLUMENATE Global (Global Study of a 
Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal 
Lesions),13 the in-stent restenosis (ISR) cohort of ILLUMENATE 
Global, ILLUMENATE PK9 (Pharmacokinetic Study of Drug-
coated Angioplasty Balloons in the Superficial Femoral or 
Popliteal Arteries, a pharmacokinetic study of 25 patients), 
and ILLUMENATE FIH14 (CVI Drug-coated Balloon First in 
Human Trial) are single-arm studies. The SAVER trial (Stellarex 
Vascular E-Registry) is an ongoing prospective, multicenter, 
real-world registry. All trials were approved by independent 
institutional review boards or ethics committees and all 
patients provided written informed consent. Adverse events 
were reported by the investigational sites, and each site 
was monitored for data accuracy and completeness. On-site 
monitoring was performed for all trials except SAVER, where 
remote monitoring was used. Adverse events occurring within 
the follow-up period of each trial were independently adju-
dicated by a blinded Clinical Events Committee (CEC) that 
comprised varied specialists. Variables from the 7 individual 
studies were harmonized to account for different variable 
names and units and to create one master variable list for all 
studies. The data sets were merged using R software (version 
3.5.2, R Foundation for Statistical Computing).
Interventions
The 0.035-inch platform DCB was used for intervention in all 
studies. The device is intended for use in patients with PAD 
to treat de novo or restenotic lesions. The DCB consists of an 
over-the-wire dual-lumen catheter with a distally mounted 
semicompliant inflatable balloon and an atraumatic tapered 
tip. The balloon’s proprietary coating (EnduraCoat) contains a 
hybrid balance of amorphous and crystalline paclitaxel at a uni-
form concentration of 2 µg/mm2 as the active pharmaceutical 
agent with a polyethylene glycol excipient. Preclinical evidence 
demonstrated high coating stability with limited distal emboli-
zation and high drug transfer efficiency.15 A minimum inflation 
time of 60 seconds is recommended in the instructions for use.
Outcomes
The outcome for the meta-analysis is time to death. Patients 
who did not reach the end point by 3 years were censored 
at their last day of contact or 3 years, whichever came first. 
Deaths were adjudicated by the independent CEC (see the 
online-only Data Supplement Appendix). Causes of death were 
classified by a designated Safety Officer, using the Medical 
Dictionary for Regulatory Activities (MedDRA) terminology 
(version 21.0, MedDRA MSSO) System Organ Classes. CEC-
adjudicated deaths were grouped into those that were cardio-
vascular-related or non–cardiovascular-related. Undetermined 
causes of death were classified as non–cardiovascular-related.
Statistical Methods
A key objective of this investigation was to develop a model of 
predictors of the mortality in patients treated with DCBs. The 
hazard rate for mortality (MHR) was used to assess mortality 
in the 7 Stellarex studies. Unlike the hazard ratio (HR), which 
compares 2 groups like test versus control, the MHR measures 
the instantaneous speed at which deaths are accumulating over 
time for the population being evaluated. To assess the hetero-
geneity of outcome among the studies, a 2-stage meta-analy-
sis of individual patient data was performed by using Stata/IC 
(version 15.1, StataCorp LLC). The I2 statistic was calculated to 
assess the percentage of variation across studies attributable to 
heterogeneity rather than chance alone.16
The Student t test was used for comparisons of continu-
ous variables and the Fisher exact test was used for categorical 
variables. Continuous variables were presented as mean±SD or 
median (range). Kaplan–Meier methodology was used to esti-
mate hazard rates of all-cause mortality, and the restricted mean 
survival time was used to compare outcome in the randomized 
treatment arms. Cox proportional hazards modeling was used 
to assess the relationship between baseline and demographic 
characteristics and mortality. Candidate variables included base-
line and demographic characteristics, treatment (DCB or PTA), 
and paclitaxel exposure. Exposure, the total amount of drug 
per patient, was calculated by size (diameter and length) and 
the number of devices used during treatment. A univariate Cox 
model was done for each candidate variable. Variables with 
>15% of values missing were excluded. Imputation of missing 
data for the remaining variables was performed by using sex-
specific mean substitution for continuous variables and mode 
imputation for categorical variables. A P value of <0.25 was used 
for entry in the multivariable Cox model. Variables were elimi-
nated stepwise until the P value for each was <0.05. A second 
multivariable Cox model was done in the same manner, with the 
exception that paclitaxel exposure was forced into the model. 
HRs and 95% confidence intervals were calculated. P values of 
<0.05 were considered statistically significant. With the excep-
tions of data mapping and heterogeneity assessments, SAS (ver-
sion 9.4, SAS Institute) was used for the statistical analyses.
RESULTS
Demographic and Baseline Characteristics
Demographic and baseline characteristics were not sta-
tistically different in the DCB and PTA arms of the 2 
pooled randomized trials (Tables 2 and 3), with 2 ex-
ceptions. Patients in the pooled DCB arm were slightly 
younger (67.4±9.7 versus 69.4±9.4 years, DCB versus 
PTA, P=0.02) and were more often smokers (86.6% 
versus 78.8%, DCB versus PTA, P=0.02). The median 
exposure of paclitaxel in the DCB-treated patients was 
3.9 mg (interquartile range, 2.6–6.5 mg). Study design 
and therefore patient demographics were not collected 
in the same detail as the RCTs. Therefore, only the RCT 
trial patient demographics are reported.
Combining Data Sets
An assessment of poolability among the 7 Stellarex 
studies was done in preparation for the identification 
of covariates predictive of death after treatment. The 
estimated MHR for each of the trials declined at a con-
stant rate. The 2 RCTs, ILLUMENATE EU RCT and ILLU-
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MENATE Pivotal, had MHRs that were almost identical, 
3.95% (95% CI, 2.78%–5.62%) and 3.81% (95% CI, 
2.78%–5.63%), respectively (Figure 1). The I2 statistic 
was 0.0% (P=0.89), confirming the homogeneity for 
the 2 Stellarex RCTs. Given that the protocols, clinical 
operations, and baseline demographics were similar 
and the effects sizes were almost identical, the 2 RCTs 
were pooled for the analysis of mortality after treat-
ment with DCB versus PTA.
The annualized MHR in patients treated with DCB 
shows that the ILLUMENATE PK study was an outlier 
among the 7 Stellarex studies (Figure 2). The study had 
25 patients with 0 deaths. The I2 statistic was 47.3% 
(P=0.08) when all 7 studies were included, suggesting 
a moderate level of heterogeneity.17 After elimination 
of the ILLUMENATE PK study from the analysis, the I2 
statistic decreased to 38.6% (P=0.15), indicating mod-
erately low heterogeneity. Eliminating the ILLUMENATE 
FIH study decreased the I2 to 27.8% (P=0.24), but the 
decision was made to combine all studies, only elimi-
nating ILLUMENATE PK for the Cox modeling of covari-
ates predictive of mortality. Among the 2523 subjects in 
the 7 studies, 25 subjects in the ILLUMENATE PK study 
were excluded from combining the studies, as were 3 
additional SAVER patients with missing values that pre-
cluded sex-specific imputation; accounting for a total 
of 28 patients that were excluded from the combined 
data set. There were no deaths in the 28 subjects that 
were excluded from the combined analysis. In total, 
2495 patients remained in the combined analytic data 
set of the remaining 6 studies; 2325 DCB-treated sub-
jects and 170 subjects treated with PTA.
All-Cause Mortality
In the 589 patients enrolled in the RCT trials, death oc-
curred in 35 of 419 patients treated with DCB (8.4%) 
and 15 of 170 patients treated with PTA (8.8%) within 
3 years of the index procedure. There was no significant 
difference in all-cause mortality between the 2 cohorts 
through full follow-up of 3 years (Figure 3, P=0.86, re-
stricted mean survival time analysis). The proportion of 
patients lost to follow-up was low: 3.7% in the ILLUMI-
NATE EU and 2.3% in ILLUMENATE Pivotal RCTs. Sub-
Table 2. Baseline and Demographic Characteristics of Patients in the 2 RCTs: Categorical Variables
Characteristic
ILLUMENATE EU RCT ILLUMENATE Pivotal RCT Pooled RCTs
P ValueDCB PTA DCB PTA DCB PTA
Patients in cohort 219 70 200 100 419 170  
Male sex 71.7% (157/219) 67.1% (47/70) 56.0% (112/200) 64.0% (64/100) 64.2% (269/419) 65.3% (111/170) 0.85
Hypertension 77.6% (170/219) 82.9% (58/70) 93.5% (187/200) 94.0% (94/100) 85.2% (357/419) 89.4% (152/170) 0.19
Hyperlipidemia 61.6% (135/219) 68.6% (48/70) 88.0% (176/200) 90.0% (90/100) 74.2% (311/419) 81.2% (138/170) 0.09
Myocardial infarction 13.2% (29/219) 17.1% (12/70) 21.0% (42/200) 22.0% (22/100) 16.9% (71/419) 20.0% (34/170) 0.41
Angina 6.8% (15/219) 7.1% (5/70) 15.0% (30/200) 20.0% (20/100) 10.7% (45/419) 14.7% (25/170) 0.21
Congestive heart failure 6.4% (14/219) 8.6% (6/70) 12.0% (24/200) 8.0% (8/100) 9.1% (38/419) 8.2% (14/170) 0.87
Renal insufficiency 9.1% (20/219) 8.6% (6/70) 18.0% (36/200) 17.0% (17/100) 13.4% (56/419) 13.5% (23/170) >0.99
Chronic pulmonary disease 16.0% (35/219) 10.0% (7/70) 16.0% (32/200) 21.0% (21/100) 16.0% (67/419) 16.5% (28/170) 0.90
Diabetes mellitus 37.0% (81/219) 35.7% (25/70) 49.5% (99/200) 52.0% (52/100) 43.0% (180/419) 45.3% (77/170) 0.65
Previous peripheral 
revascularization
20.5% (45/219) 20.0% (14/70) 45.0% (90/200) 48.0% (48/100) 32.2% (135/419) 36.5% (62/170) 0.34
Smoking
  Current 49.8% (109/219) 48.6% (34/70) 35.5% (71/200) 36.0% (36/100) 43.0% (180/419) 41.2% (70/170) 0.05
  Previous 39.3% (86/219) 34.3% (24/70) 48.5% (97/200) 40.0% (40/100) 43.7% (183/419) 37.6% (64/170)
  Never 11.0% (24/219) 17.1% (12/70) 16.0% (32/200) 24.0% (24/100) 13.4% (56/419) 21.2% (36/170)
Rutherford category
  2 15.1% (33/219) 20.3% (14/69) 31.5% (63/200) 35.0% (35/100) 22.9% (96/419) 29.0% (49/169) 0.23
  3 83.1% (182/219) 78.3% (54/69) 64.5% (129/200) 60.0% (60/100) 74.2% (311/419) 67.5% (114/169)
  4 1.8% (4/219) 1.4% (1/69) 4.0% (8/200) 5.0% (5/100) 2.9% (12/419) 3.6% (6/169)
Lesion type
  De novo 91.8% (201/219) 90.0% (63/70) 90.5% (181/200) 82.0% (82/100) 91.2% (382/419) 85.3% (145/170) 0.04
  Recurrent 8.2% (18/219) 10.0% (7/70) 9.5% (19/200) 18.0% (18/100) 8.8% (37/419) 14.7% (25/170)
Calcification 44.3% (97/219) 41.4% (29/70) 65.7% (130/198) 68.0% (68/100) 54.4% (227/417) 57.1% (97/170) 0.58
DCB indicates drug-coated balloon; PTA, uncoated percutaneous transluminal angioplasty; and RCT, randomized, controlled trial.
Gray et al Analysis of Mortality in SFA DCB Therapy
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jects voluntarily withdrawing before completion in the 
studies was 12.2% of ILLUMENATE EU and 7.0% of IL-
LUMENATE Pivotal trials. The 1-year (360-day) Kaplan–
Meier estimate of all-cause mortality was 1.8±0.7% 
(estimate±SE) in the DCB cohort and 1.3±0.9% in the 
PTA cohort. At 2 years (720 days), all-cause mortality 
was 6.5±1.3% in the DCB cohort versus 5.9±1.9% in 
the PTA cohort. At 3 years (1080 days), all-cause mor-
tality was 9.3±1.5% in the DCB cohort and 9.9±2.4% 
in the PTA cohort.
In the cohort of 2325 DCB-treated patients from the 
6 combined studies, 80 deaths (3.4%) occurred through 
3 years. The 1-, 2-, and 3-year Kaplan–Meier estimates 
of all-cause mortality were 2.0±0.4%, 5.6±0.7%, and 
8.0±0.9%, respectively, in the 6 combined studies (Fig-
ure 4). The corresponding estimates for the 1906 DCB-
treated patients enrolled in the 4 combined nonrandom-
ized studies were not clinically different from the rates in 
the RCTs; 2.1±0.4% at 1 year, 4.9±0.8% at 2 years, and 
7.0±1.1% at 3 years after treatment (Figure 5).
Adjudicated Causes of Death
The causes of death are summarized in Table  4, 
categorized by MedDRA System Organ Classes. The 
CEC-adjudicated cause of death through 3 years was 
Table 3. Baseline and Demographic Characteristics of Patients in the 2 RCTs: Continuous Variables
Characteristic
ILLUMENATE EU RCT ILLUMENATE Pivotal RCT Pooled RCT
P Value*DCB PTA DCB PTA DCB PTA
Patients in cohort 219 70 200 100 419 170  
Age, y
  N 219 70 200 100 419 170 0.02
  Mean 66.8±9.2 69.0±8.7 68.2±10.3 69.7±9.8 67.4±9.7 69.4±9.4
Ankle brachial
  N 214 67 197 100 411 167 0.63
  Median 0.7(0.0–1.4) 0.7(0.0–1.5) 0.8(0.0–1.8) 0.8(0.0–1.3) 0.7(0.0–1.8) 0.7(0.0–1.5)
Lesion length, mm
  N 219 70 200 100 419 170 0.10
  Mean 91.3±51.3 94.7±57.3 85.1±41.5 96.1±41.7 88.3±46.9 95.5±48.5
Reference vessel diameter, mm
  N 218 70 200 100 418 170 0.44
  Mean 5.0±0.8 4.8±0.7 4.9±0.9 5.2±1.1 4.9±0.9 5.0±0.9
Diameter stenosis, % reduction
  N 218 70 200 100 418 170 0.87
  Mean 81.7±14.3 83.1±14.2 73.9±16.9 74.8±17.0 77.9±16.0 78.2±16.4
Paclitaxel dose, mg
  N 219 70 200 100 419 NA NA
  Median 4.3(1.1–15.8) NA 3.9(1.3–9.4) NA 3.9(1.1–15.8) NA
Data are expressed as mean±SD or median (range). DCB indicates drug-coated balloon; PTA, percutaneous transluminal angioplasty; NA, not applicable; and RCT, 
randomized, controlled trial.*P value for the comparison of the DCB and PTA cohorts of the pooled RCTs.
Figure 1. Hazard rates for mortality for 
drug-coated balloon arms of the 2 random-
ized, controlled trials (RCTs).  
The Pivotal study and EU RCT had nearly identi-
cal hazard rates with an overall I2 of 0.0%, 
indicative of homogeneity. EU RCT indicates 
CVI Drug-coated Balloon European Random-
ized Clinical Trial; and PIVOTAL, Pivotal Trial 
of a Novel Paclitaxel-coated Percutaneous 
Angioplasty Balloon.
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cardiovascular in 20 patients (25%) and noncardiovas-
cular in 60 patients (75%). Among the non–cardiovas-
cular-related deaths in the patients treated with DCB, 17 
(21%) were of undetermined cause at the time of this 
analysis. In the 15 deaths in the PTA cohort, the adju-
dicated cause was cardiovascular in 4 (27%) and non-
cardiovascular in the remaining 11 (73%). The higher 
proportion of deaths of undetermined cause in the non-
Figure 2. Hazard rates for mortality in 
 patients treated with drug-coated balloons. 
A, The hazard rates for mortality in patients 
treated with drug-coated balloons (DCBs) in the 
7 Stellarex studies. Patients treated with DCBs 
in the 7 Stellarex studies had an overall I2 of 
47.3%, consistent with moderate heteroge-
neity. ILLUMENATE PK was an outlier, with a 
hazard rate of 0.10. B, Annualized hazard rates 
for mortality for patients treated with DCBs in 
the 6 Stellarex studies. After elimination of the 
PK study, the overall I2 decreased to 38.6%, 
reflecting moderately low heterogeneity in the 
6 remaining studies. EU RCT indicates CVI Drug-
coated Balloon European Randomized Clinical 
Trial; FIH, first in human; GLOBAL, Global Study 
of a Drug-coated Balloon to Treat Obstruc-
tive SFA and/or Popliteal Lesions; ISR, in-stent 
restenosis; PIVOTAL, Pivotal Trial of a Novel 
Paclitaxel-coated Percutaneous Angioplasty 
Balloon; PK, pharmacokinetic; RCT, randomized, 
controlled trial; and SAVER-E, Stellarex Vascular 
E-Registry.
Figure 3. Survival in the pooled randomized, 
controlled trials (RCTs).  
The pooled RCTs show no significant differences in the 
survival rates in the 2 groups through 3-year (1080-
day) follow-up. For further information about pooling, 
refer to the combining data sets section of the article. 
The P value tests the null hypothesis that restricted 
mean survival time (RSMT) for the 2 curves are equal vs 
the alternative that they are not equal. DCB indicates 
drug-coated balloon; and PTA, uncoated percutaneous 
transluminal angioplasty.
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randomized DCB cohort was attributable to yet unde-
termined causes of death in the ongoing SAVER registry.
The most common CEC-adjudicated cause of death 
after DCB treatment was a cardiac disorder, responsible 
for 19 of 80 deaths (23.8%), followed by neoplasms 
(18/80 deaths, 22.5%). In the PTA cohort, general dis-
orders were the most common cause of death (5/15, 
33.3%), followed by cardiac disorders (4/15, 26.7%) 
and neoplasms (2/15, 13.3%). There were no device- 
or procedure-related deaths adjudicated in the entire 
series of 2523 patents.
Predictors of Mortality After DCB 
Treatment
The Cox proportional hazards analysis of mortality in 
the 6 combined studies included 2495 patients: 589 
patients from the 2 RCTs and 1906 patients from the 4 
nonrandomized studies. The univariate analysis includ-
ed 16 candidate baseline variables, 7 of which had HRs 
with P values of <0.05 (Table 5).
Among the 16 candidate variables, 10 had univariate 
HRs with P values of <0.25 and were entered into the 
multivariable Cox proportional hazards model. Variables 
were eliminated stepwise until the P value for each re-
maining variable was <0.05. The final model identified 
4 significant predictors of mortality (Table 6); age (HR, 
1.06; 95% CI, 1.04–1.08; P<0.001), diabetes mellitus 
(HR, 1.43; 95% CI, 1.01–2.01; P=0.04), congestive 
heart failure (HR, 1.86; 95% CI, 1.11–3.12; P=0.02), 
and renal insufficiency (HR, 2.00; 95% CI, 1.33–3.01; 
P<0.001). When treatment (DCB versus PTA) was 
forced into the model to assess its effect on the risk of 
death, the use of a DCB was not a predictor of mortality 
(HR, 1.18; 95% CI, 0.75–1.87; P=0.47). Similarly, when 
paclitaxel exposure (mg) was forced into the model as a 
continuous variable, exposure did not predict mortality 
(HR, 1.04; 95% CI, 0.98–1.10; P=0.23).
Figure 4. Survival through 3 years (1080 days) in 
the 6-study pooled data set.  
The ILLUMENATE PK study (Pharmacokinetic Study of 
Drug-coated Angioplasty Balloons in the Superficial 
Femoral or Popliteal Arteries) was excluded because 
there were no deaths. The Kaplan–Meier estimates 
are reported for each year. DCB indicates drug-coated 
balloon.
Figure 5. Survival through 3 years in the 4 nonran-
domized, pooled studies.  
The 3-year mortality estimate for the ILLUMENATE FIH 
(CVI Drug-coated Balloon First in Human Trial), ILLUME-
NATE Global (Global Study of a Drug-Coated Balloon 
to Treat Obstructive SFA and/or Popliteal Lesions), 
Global-ISR (in-stent restenosis), and SAVER (Stellarex 
Vascular E-Registry) studies was 7.0% by Kaplan–Meier 
methodology. DCB indicates drug-coated balloon.
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DISCUSSION
A recent systematic review and summary-level meta-
analysis by Katsanos et al12 raised safety concerns 
related to the use of paclitaxel balloons and stents 
for treating femoropopliteal arterial disease. The cur-
rent analysis was undertaken to further confirm the 
previously reported safety profile of the Stellarex 
DCB.7,9,13,14,18,19 In contrast to the methodology used 
by Katsanos, the current study used an independent 
analysis of patient-level data, a single DCB device, and 
poolable studies. ILLUMENATE PK, a small study with 
no deaths, was excluded from the analysis because of 
its heterogeneity. The present findings differ substan-
tially from those of the Katsanos meta-analysis. The 
current study of the combined Stellarex RCTs showed 
that patients in the DCB cohort had mortality rates 
comparable to those in the PTA cohort, an observa-
tion that must be considered in the context of the size 
of the ILLUMENATE studies, none of which were ad-
equately powered to detect differences in long-term 
mortality. Nonetheless, pooling of patients from the 
RCT data sets strengthens the validity of the analy-
ses. The current findings confirm and are consistent 
with the previously reported findings from the ILLU-
MENATE femoropopliteal clinical program that dem-
onstrated the strong safety and efficacy DCB at 1 and 
2 years.9,14,19
Paclitaxel is a cytostatic and cytotoxic agent com-
monly used for cancer chemotherapy. With the advent 
of local drug delivery technologies, paclitaxel-eluting 
coronary stents were demonstrated to be effective in 
the reduction of clinical restenosis in percutaneous cor-
onary interventions.20 However, first-generation coro-
nary paclitaxel-eluting coronary stents were subject 
to slightly higher rates of stent thrombosis than bare 
metal stents.21 Despite this hazard, paclitaxel-eluting 
stents have not been shown to have excess mortal-
ity in comparison with bare metal stents.22–24 When 
used in the femoropopliteal arteries, paclitaxel-coat-
ed balloons such as the Stellarex DCB have reduced 
restenosis, yielding improved long-term patency.3,14 
Paclitaxel exerts its antirestenotic properties through 
the prevention of smooth muscle cell proliferation 
by blocking mitosis.25–27 Paclitaxel DCBs used in the 
Table 4. Causes of Death in Patients Treated With Paclitaxel-Coated 
Balloons as Adjudicated by the Clinical Events Committee (MedDRA 
System-Organ Classes)
Cause of Death
Pooled 
Studies* Non-RCTs* Pooled RCTs
DCB
n=2325
DCB
n=1906
DCB
n=419
PTA
n=170
Cardiac 
disorders
19/80 (24%) 11/45 (24%) 8/35 (23%) 4/15 (27%)
Gastrointestinal 
disorders
1/80 (1%) 0/45 (0%) 1/35 (3%) 1/15 (7%)
General 
disorders
8/80 (10%) 5/45 (11%) 3/35 (9%) 5/15 (33%)
Hepatobiliary 
disorders
1/80 (1%) 0/45 (0%) 1/35 (3%) 1/15 (7%)
Infections and 
infestations
5/80 (6%) 2/45 (4%) 3/35 (9%) 0/15 (0%)
Injury/poisoning/
procedural
1/80 (1%) 0/45 (0%) 1/35 (3%) 0/15 (0%)
Metabolism and 
nutritional
1/80 (1%) 0/45 (0%) 1/35 (3%) 0/15 (0%)
Neoplasms 
benign, 
malignant
18/80 (23%) 6/45 (13%) 12/35 (34%) 2/15 (13%)
Nervous system 
disorders
1/80 (1%) 1/45 (2%) 0/35 (0%) 0/15 (0%)
Renal and 
urinary disorders
0/80 (0%) 0/45 (0%) 0/35 (0%) 1/15 (7%)
Respiratory/
thoracic/
mediastinal
7/80 (9%) 3/45 (7%) 4/35 (11%) 1/15 (7%)
Vascular 
disorders
1/80 (1%) 0/45 (0%) 1/35 (3%) 0/15 (0%)
Undetermined 17/80 (21%) 17/45 (38%) 0/35 (0%) 0/15 (0%)
Total deaths 
through 3 y
80/2325 
(3.4%)
45/1906 
(2.4%)
35/419 
(8.4%)
15/170 
(8.8%)
DCB indicates drug-coated balloon; MedDRA, Medical Dictionary for 
Regulatory Activities; PTA, percutaneous transluminal angioplasty; and RCT, 
randomized, controlled trial.
*Data comprise pooled data sets. There were no deaths in the 28 patients 
excluded from the pooled analysis.
Table 5. Univariate Cox Proportional Hazards Analysis of Baseline and 
Demographic Predictors of Mortality
Covariate
Hazard Ratio  
(95% CI) P Value
Male sex 1.08 (0.76–1.55) 0.66
Age, per year 1.07 (1.05–1.09) <0.01
Lesion length, per mm 1.00 (0.99–1.00) 0.14
Hypertension 0.98 (0.63–1.54) 0.94
Hyperlipidemia 0.97 (0.66–1.44) 0.90
Myocardial infarction 0.98 (0.62–1.55) 0.93
Angina 1.01 (0.58–1.76) 0.97
Renal insufficiency 2.93 (1.98–4.34) <0.01
Congestive heart failure 2.32 (1.40–3.86) 0.01
Diabetes mellitus 1.45 (1.03–2.03) 0.03
Smoking history* 0.58 (0.39–0.86) 0.01
Previous peripheral vascular procedure 1.26 (0.90–1.79) 0.18
Rutherford 2 vs 3 0.79 (0.52–1.22) <0.01
Rutherford 4 vs 3 2.15 (1.22–3.79)
Rutherford 5 vs 3 4.53 (1.66–12.38)
Lesion type, de novo 0.72 (0.45–1.16) 0.17
Calcification 1.47 (1.02–2.11) 0.04
Paclitaxel dose, per mg 1.02 (0.96–1.08) 0.53
*Hazard ratio for smokers, current and prior.
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femoropopliteal segment have consistently demon-
strated improved target vessel patency, with signifi-
cant reduction in late lumen loss and target vessel 
revascularization.4,6,7,9,10,28–30
Paclitaxel, when delivered systemically for breast, 
lung, and other malignancies, is used in significantly 
higher concentrations than the doses used in peripheral 
vascular applications.5 In larger doses, the common side 
effects of paclitaxel include anemia, gastrointestinal 
symptoms, and renal impairment. Other less common 
side effects include allergic/hypersensitivity reactions, 
liver toxicity, neurotoxicity, and cardiac rhythm changes. 
Outside the toxic reactions leading to death in chemo-
therapy drug trials for patients with cancer, there are 
no substantive preclinical or patient-level clinical studies 
correlating the mechanism of action of paclitaxel with 
long-term side effects leading to death, including those 
associated with treatment of PAD.
The meta-analysis by Katsanos et al12 concluded 
that there is an increased late mortality risk after the 
application of paclitaxel-coated balloons and stents 
in the femoropopliteal arteries of the lower limbs. 
However, the study has several limitations. The study 
combined RCTs and examined multiple devices of dif-
ferent applications and doses, including both DCBs 
and drug-eluting stents.12 Patient-level data were un-
available to the authors, precluding a granular level of 
detail for causes of death. In addition, the reporting of 
death rates used by the study was inconsistent; some 
studies reported event frequency within time inter-
vals, whereas others reported the rates cumulatively.12 
Last, despite the inclusion of 28 RCTs in the analysis, 
the mortality conclusions were based on considerably 
fewer presentations and publications where extended 
follow-up was available.
The findings of 2 recently published comparisons 
of DCB to PTA failed to support the conclusions of 
Katsanos. Schneider et al31 published outcomes of 
a patient-level meta-analysis comprising 2 RCTs and 
2 single-arm trials of 1980 patients: 1837 patients 
treated with a higher-dose paclitaxel-coated balloon 
from a single manufacturer and 143 patients treated 
with uncoated PTA. Overall, there was no statistically 
significant difference in all-cause mortality between 
patients treated with DCB versus PTA through 5-year 
follow-up (15.1% versus 11.2%, P=0.09).31 In the 
second recent publication, Secemsky and colleagues32 
evaluated all-cause mortality in a retrospective analy-
sis of 16 560 Medicare and Medicaid beneficiaries 
treated for femoropopliteal disease during calendar 
year 2016. The authors were unable to detect an as-
sociation between all-cause mortality and the use of 
DCBs or drug-eluting stents, with a HR of 0.97 (95% 
CI, 0.91–1.04; P=0.20). The failure to find a differ-
ence, however, is confounded by median follow-up 
of ≈1 year in this study. This duration may have been 
too short to observe differences in mortality, differ-
ences that became evident at 2 years in the analysis 
of Katsanos et al.33
Currently, there are many RCTs with superior ef-
ficacy results for DCB therapy over uncoated PTA for 
femoropopliteal lesions.,4,6,7,9,10,13,14,19,28 These DCB tri-
als have often met their primary safety outcomes and 
shown durable safety outcomes. Although DCBs intro-
duce risks as with any endovascular procedure, study 
results confirm long-term patency, thereby reducing 
the rate of reinterventions. Current opinion suggests 
that the benefits continue to outweigh the risks associ-
ated with DCB.1,34,35
We recommend further adequately powered meta-
analyses of RCTs studying paclitaxel-coated DCBs to 
test the generalizability of the results presented here. 
Further analyses with cross-industry collaboration, in-
cluding any associations between device-specific char-
acteristics (eg, paclitaxel dosage, coating morphology) 
may be warranted. In light of questions raised by the 
Katsanos meta-analysis, continued enrollment and 
long-term follow-up of patients treated with DCBs is 
needed to further reinforce the safety profile of pacli-
taxel-coated DCBs for the treatment of femoropopli-
teal PAD.
Limitations
The analysis was limited by the size of the 2 combined 
RCTs with many fewer patients in the PTA arms, 170 
versus 419, and the ongoing follow-up in some of the 
trials without complete follow-up in all patients, as 
well. Even together, the trials lacked enough power 
to ensure the absence of mortality differences. An ad-
equately powered study to identify a clinically relevant 
reduction of 50% from the annual rates from our DCB 
studies would require a sample size of from 1600 to 
6000 randomly assigned patients with at least 3 years 
Table 6. Multivariable Cox Proportional Hazards Model for Mortality
Covariate Hazard Ratio (95% CI) P Value
Without forcing drug dose into the model
  Age, per year 1.06 (1.04–1.08) <0.01
  Congestive heart failure 1.86 (1.11–3.12) 0.02
  Diabetes mellitus 1.43 (1.01–2.01) 0.04
  Renal Insufficiency 2.00 (1.33–3.01) <0.01
With drug dose forced into the model
  Age, per year 1.06 (1.04–1.08) <0.01
  Congestive heart failure 1.89 (1.12–3.19) 0.02
  Diabetes mellitus 1.45 (1.03–2.04) 0.04
  Renal insufficiency 2.03 (1.35–3.06) <0.01
  Paclitaxel dose, per mg 1.04 (0.98–1.10) 0.23
Multivariate predictors were chosen with a stepwise procedure using an 
entry criterion 0.25 and a stay criterion of 0.05.
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of follow-up. Although samples size calculations de-
pend on the eligibility criteria and mortality rates that 
may differ from the current study, an adequately pow-
ered study would still be much larger than the current 
DCB trials. Also, in our comparison of the 2 RCTs, we 
assumed that patients in the PTA arms were paclitax-
el-naïve. However, some patients who received PTA 
may have been exposed to paclitaxel with other DCBs 
or drug-eluting stents before enrollment, for instance 
in the contralateral limb, or during the follow-up pe-
riod. Our analysis may then underestimate the num-
ber of patients treated with any paclitaxel, a limitation 
inherent with many analyses in the field. In addition, 
in some studies, as many as 3% of patients were lost 
to follow-up. Because the mortality rates are low, this 
may represent a limitation to statistical analysis. Sepa-
rately, when combining the studies from the Stellarex 
femoropopliteal clinical program, discrepancies exist 
between the manner with which data were collected as 
part of RCTs and data were collected for single-arm tri-
als and registries. Heterogeneity among trials could not 
be completely eliminated, while adding more events to 
the analysis resulted in a loss of some degree of ho-
mogeneity in the aggregate analytic data set. Finally, 
commercially available DCBs differ in paclitaxel dosage, 
excipient, and other properties specific to each device. 
Therefore, the current observations with the Stellarex 
DCBs may not be applicable to other DCBs.
Conclusions
Results from this systematic combined analysis of 3-year 
data from the Stellarex femoropopliteal clinical program 
demonstrate no significant difference in mortality rates 
in patients treated with a paclitaxel DCB and PTA. No 
device- or procedure-related deaths were reported. Al-
though further research with larger RCT data sets is en-
couraged to test the generalizability of these results, the 
data presented in this article do not confirm the findings 
of Katsanos et al. Within the context of studies that were 
not powered to detect mortality differences, Stellarex 
DCB remains a viable alternative in the treatment of PAD.
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